Alkermes (ALKS) Granted FDA Fast Track Designation for Nemvaleukin Alfa in Combination With Pembrolizumab for the Treatment of Platinum-Resistant Ovarian Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. IONQ
2. IONS
3. AZN
4. SPY
5. ROIV
6. AAPL
7. NVDA
8. ACN
9. ODFL
10. USO

Go back to Alkermes (ALKS) Granted FDA Fast Track Designation for Nemvaleukin Alfa in Combination With Pembrolizumab for the Treatment of Platinum-Resistant Ovarian Cancer
ALKERMES (NASDAQ: ALKS) Delayed: 46.07 -0.03 (0.07%)
Previous Close $46.10    52 Week High $80.71 
Open $45.20    52 Week Low $27.14 
Day High $46.29    P/E 354.38 
Day Low $44.63    EPS $0.13 
Volume 214,669